Accendra Health, Inc. (ACH)
Healthcare
- Fundamental
- 1
- Sentiment
- 2
- Technical
- 1
Do Nothing: fundamentalScore 1 and qualitativeScore 2 both sit below the required floor of 3, and the 20-day average dollar volume of ~$1.0M is below the $5M liquidity floor, so no long entry is admissible regardless of the chart; independently no setup qualifies — the pullback limit is countertrend (price 0.132 < sma50 0.51 with macdLine -0.10) and the breakout stop has no base to clear at a fresh 52-week low 0.12 with every moving average overhead.
Company overview
Accendra Health, Inc. provides healthcare solutions globally, operating through two divisions: Products & Healthcare Services and Patient Direct. The company offers medical supplies, logistics, and at-home patient care products, serving healthcare systems and providers.
Fundamental
very weakAccendra Health faces severe financial distress with negative equity, shrinking revenues, and significant debt challenges.
Deeply distressed post-divestiture home medical equipment operator: negative $568 million book equity, a 0.41 current ratio, interest coverage of 0.31 times, negative operating and free cash flow, roughly $1.75 billion of debt trading near 68 cents on the dollar, and two NYSE listing deficiency notices. The Patient Direct business is shrinking faster than management's turnaround plan can offset, and the common equity reads as a speculative restructuring option rather than an investable business.
Sentiment
weakMedia sentiment is negative, with unresolved NYSE listing issues and management changes contributing to uncertainty.
The dominant driver is the announced 2026-11-05 Q3 print — revenue down ~1% with FY adjusted EBITDA guidance cut up to 30% — compounded by a live, unresolved NYSE continued-listing deficiency (Section 802.01B, ongoing process) that keeps a delisting path open; the only offset is the 2026-11-02 extension of the $150M receivables sale program to 2029, which the tape rewarded (~+25%). The 14-day media read is negative in absolute terms (aggregate polarity_score ≈ -0.17 across 7 scored items) while the sentiment delta is indeterminate (the baseline produced a single scorable item), and two moderate red flags fired — conflicting catalyst signals and a COO departure without a named successor — so a moderate red-flag cap applies.
Technical
very weakThe stock is in a mature downtrend, trading below all moving averages with no support levels, indicating continued weakness.
Score 1/5 — broken structure, not merely weak. Price 0.132 sits below SMA20 (0.22), SMA50 (0.51), SMA200 (2.14), EMA9 (0.18), EMA21 (0.25), WMA9 (0.17), WMA21 (0.21), DEMA14 (0.14) and TEMA14 (0.16): a fully stacked bearish alignment with every average overhead. The 2026-11-13 session closed at a new 52-week low (regular range 0.1200-0.1375 against a 4.69 year high) and essentially at session VWAP (0.13175). ADX14 51.04 — down from 64.79 eleven sessions ago but still unambiguous trend strength — read alongside price below all moving averages denotes a strong persistent DOWN trend, not a base. Momentum is deeply oversold (RSI14 22.84, Williams %R -94.29) with MACD line -0.10 below signal -0.12 but histogram fractionally positive (+0.01): a flattening, still-negative configuration that supports at most a reflex bounce inside a downtrend. Volume quality is poor and deteriorating: avgDollarVolume20 ~$1.00M is carried by a single 34.4M-share session on 2026-11-02, while the last three regular sessions averaged only ~$315K/day. Even with perfect upstream scores this chart could not support a 1-15 day long: the trend, structure, liquidity and momentum frames all point the same way.
You’re looking at 2026-11-15 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

